The Effects of BTK Inhibitors on Response Rates

The mutation profile has nothing at all to do with cyclophosphamide, bortezimibendomustine. It only really has been shown to be important in patients who elect a brute nib. If you were wild type, M-Y-D-88, it was a 70% or 65%, would you not consider it as an option? Probably not for first line.